Eli Lilly reported third-quarter adjusted earnings of $7.48 per share and revenue of $24.40 billion, both above analyst estimates of $6.26 and $22.61 billion. The company raised its 2026 revenue forecast to $91–92 billion from $85–87 billion, while its adjusted earnings outlook was lowered to $35–36 per share from $35.50–36.50, reflecting $4.57 per share in deal-related charges. Mounjaro revenue rose 65% to $10.72 billion and Zepbound reached $5.35 billion, up 49%, while the new obesity pill Foundayo brought in $184 million, below forecasts of about $229 million. Net income was $6.45 billion, or $7.22 per share, including those deal charges.
Summary written by Upside AI from the original article. Read the source for full details.
Keywords
Eli Lillypharmaceuticalsearnings
Open a keyword to see other news on the same topic.
Related news
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Eli Lilly shares rose over 6% to about $1,370, a record closing high, after third-quarter revenue jumped 39% year over year to $24.4 billion, above the LSEG consensus of $22.6 billion. Adjusted EPS rose 6.6% to $7.48, beating analysts' $6.26 estimate, though a sizable acquisition-related accounting charge held back annual profit growth. Adjusted gross margin reached 84.4%, up from 83.6% a year earlier. Mounjaro revenue climbed 65% to $10.7 billion and Zepbound rose 49% to $5.35 billion, as higher patient volumes more than offset lower realized prices. The price target was raised to $1,500 from $1,300 and the 2 rating was reiterated, with shares up more than 50% since the April 29 close.
- Cramer sees opportunity amid tech turmoil and predicts a holiday win for FedEx
Stocks fell Thursday as weak results from several major technology companies weighed on the market, with Alphabet tumbling after missing revenue expectations despite strong Google Cloud growth, and Microsoft falling in the tech selloff despite accelerating Azure revenue growth. Jim Cramer said investors were indiscriminately selling strong companies alongside weaker ones. Eli Lilly shares hit an all-time high after a beat-and-raise quarter driven by demand for its obesity and diabetes treatments, with Lilly capturing 7 out of every 10 new participants in the Medicare GLP-1 Bridge program. FedEx beat quarterly expectations and raised its full-year outlook, but a softer fourth-quarter forecast kept gains in check, and Cramer predicted FedEx will surpass UPS for the first time in the holiday shipping season. FedEx Freight, spun off from FedEx in June, reports earnings after the bell.
- Lilly raises outlook for third time this year as Zepbound sales soar.
- These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Eli Lilly Leads Industry
- A $1,000 Investment in Eli Lilly Became $18,637. The Obesity Boom Changed Everything
Eli Lilly, once a steady insulin maker, became a major player in obesity drugs after tirzepatide, sold as Mounjaro and Zepbound, reshaped its business. A $1,000 investment ten years ago grew to $18,637 in share price terms, versus $3,634 for the S&P 500 over the same period, though these figures exclude dividends, which rose from $0.51 to $1.73 a quarter. Q2 2026 revenue rose 47.7% to $22.97 billion, and the company raised full-year guidance to $85.0–87.0 billion. Volume growth of 60% has more than offset a 13% fall in realized prices, while Lilly plans a U.S. filing for retatrutide in Q1 2027. The article notes shares fell about 22% between February 4 and April 30, 2026, before recovering.
- Lilly’s Weight-Loss Machine Gets Even Bigger
Related markets
Latest news
- Alphabet Stock Drops 12%. Can Its Dividend Survive the AI Spending Boom?
Alphabet shares fell roughly 12% to around $285 after free cash flow turned negative for a second straight quarter, reaching negative $9.07 billion in the third quarter. Capital expenditure rose 114.4% year over year to $51.36 billion, above operating cash flow of $42.29 billion, mostly for AI infrastructure. The company pays a $0.22 quarterly dividend, which took about 6.9% of operating cash flow in the second quarter ($2.689 billion), and it holds $56.33 billion in cash. The gap is being filled by $28.7 billion in net proceeds from senior notes and new shares sold through an at-the-market program, while buybacks dropped to zero in the second quarter and the program was suspended. The article judges the dividend not at major risk for now, and says the next annual dividend decision is the key signal to watch.
- US Gold Targets Debt-Funded $400M CK Gold Build as Financing Talks Advance
Executive Chairman Luke Norman of US Gold says the company is advancing financing talks for its fully permitted CK Gold Project in Wyoming, targeting a predominantly debt-funded construction package of less than 400 million USD while keeping about 25 million USD in treasury for corporate needs. The project has a reported reserve of about 1.6 million gold-equivalent ounces with an 11-year mine plan, and management aims to raise annual output toward about 100,000 ounces, with all-in sustaining costs estimated at 1,700 to 1,800 USD per ounce. Construction would take about 18 months after financing is finalized, and management would like a definitive agreement around January, though none has been announced. The company is also considering separating its Keystone exploration project in Nevada into a standalone structure.
- We're downgrading Alphabet after its rough quarter. Here's where we'd buy again
The S&P 500 and Nasdaq slipped on Thursday as post-earnings sell-offs hit technology stocks including Alphabet, ServiceNow and Fortinet. The CNBC Investing Club cut its Alphabet rating from 1 to 2 and lowered its price target to $350 from $400, but is keeping the position because of momentum in the Cloud business. The club said it would reassess if the price-to-earnings multiple falls from about 19x to the 17x-18x range and AI Mode monetization improves.
- Alphabet's Cloud Business Just Doubled. The Stock Fell 12%. Is it a Buy?
Alphabet reported third-quarter results after the close on Wednesday, and the stock fell about 10% in after-hours trading as earnings and revenue missed estimates amid heavy AI spending. Most of the earnings hit was an unrealized $8.7 billion loss on equity securities, mainly tied to its SpaceX investment, which cut EPS by $0.55, while operating income rose 30% to $40.6 billion. Google Cloud revenue more than doubled to $30.7 billion at a margin of about 36%, and its backlog reached $561 billion, up from $514 billion three months earlier. Search revenue grew 12%, down from about 17% in the second quarter, while capex of $51.4 billion pushed free cash flow to negative $9.1 billion and spending is expected to rise significantly in 2027. The author says investors are not yet convinced of the return on this spending, but that the stock's 21x forward earnings multiple after the decline may merit a closer look for long-term investors.
- Is Lockheed Martin a Buy After Its Latest Earnings Report?
Lockheed Martin shares have risen nearly 15% since last week's third-quarter results and are up 29% year to date, versus a 12% gain for the S&P 500. The company reported a record backlog of $292 billion, up 63% over the past four quarters from $179 billion, and raised its 2026 free cash flow expectation from a midpoint of $6.65 billion to $7.9 billion. Missiles and Fire Control (MFC) grew sales 24% and contributed nearly 29% of operating profit despite under 22% of revenue, while a seven-year PAC-3 contract is worth $58.6 billion. The stock trades at nearly 23 times trailing P/E versus 18 times for Northrop Grumman, and the author notes the market already prices in much of the expected growth. The author views the company as a growth story for long-term exposure to the defense sector and suggests watching for sustained sales growth that drives higher profit margins.
- Why Marvell Stock Is Down Today
Marvell Technology shares fell 13.9% as of 2:44 p.m. ET on Thursday, October 29, after Bloomberg reported that the chipmaker is in advanced talks to acquire Lumentum, a maker of optical components for AI data centers. The report said an announcement could come as early as next week, though nothing has been finalized. Marvell has about $3.93 billion in cash and equivalents, and with Lumentum's $83 billion market cap, the deal is likely to be mostly stock, which would dilute existing shareholders. Marvell's optics acquisition last year was a smaller $3.5 billion deal that included $1 billion in cash. Meanwhile, Marvell's second-quarter revenue rose 37% to a record $2.74 billion.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.